The phase II LIGHTWAVE study evaluating Sage Therapeutics' dalzanemdor for treating cognitive issues due to Alzheimer's disease fails to meet the primary goal.
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
SAGE Therapeutics (SAGE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...
Medpage Today on MSN8h
Antipsychotics Compared; Psychiatrist's Research Misconduct; Teen Suicide PredictorFormer Columbia University psychiatrist Bret Rutherford, MD, committed research misconduct by "falsely reporting that all ...
Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback